Published in J Exp Med on November 01, 1984
T cells that help B cell responses to soluble antigen are distinguishable from those producing interleukin 2 on mitogenic or allogeneic stimulation. J Exp Med (1986) 2.59
High-affinity receptor-mediated internalization and degradation of interleukin 2 in human T cells. J Exp Med (1986) 2.37
Receptors for B cell stimulatory factor 2. Quantitation, specificity, distribution, and regulation of their expression. J Exp Med (1987) 2.34
The p75 peptide is the receptor for interleukin 2 expressed on large granular lymphocytes and is responsible for the interleukin 2 activation of these cells. Proc Natl Acad Sci U S A (1987) 2.22
Expression of interleukin 2 receptors and binding of interleukin 2 by gamma interferon-induced human leukemic and normal monocytic cells. J Exp Med (1985) 1.87
Adult T-cell leukemia-derived factor/thioredoxin, produced by both human T-lymphotropic virus type I- and Epstein-Barr virus-transformed lymphocytes, acts as an autocrine growth factor and synergizes with interleukin 1 and interleukin 2. Proc Natl Acad Sci U S A (1990) 1.72
Human interleukin 2 receptor beta-chain gene: chromosomal localization and identification of 5' regulatory sequences. Proc Natl Acad Sci U S A (1990) 1.59
Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey. J Clin Immunol (2007) 1.45
Epidermal growth factor regulates the expression of its own receptor. Proc Natl Acad Sci U S A (1985) 1.41
Biological significance of soluble IL-2 receptor. Mediators Inflamm (1993) 1.33
Interleukin 6 gene expression in normal and neoplastic B cells. J Clin Invest (1989) 1.33
The human interleukin 2 receptor beta chain (p70). Direct identification, partial purification, and patterns of expression on peripheral blood mononuclear cells. J Exp Med (1988) 1.28
Bladder Cancer Immunotherapy: BCG and Beyond. Adv Urol (2012) 1.27
Tolerogenicity of resting and activated B cells. J Exp Med (1994) 1.25
Soluble Tac peptide is present in the urine of normal individuals and at elevated levels in patients with adult T cell leukaemia (ATL). Clin Exp Immunol (1988) 1.20
Immunization with antigen and interleukin 2 in vivo overcomes Ir gene low responsiveness. J Exp Med (1985) 1.16
Soluble interleukin-2 receptor in Crohn's disease: relation of serum concentrations to disease activity. Gut (1990) 1.14
Induction and upregulation by interleukin 2 of high-affinity interleukin 2 receptors on thymocytes and T cells. Proc Natl Acad Sci U S A (1985) 1.13
Prophylactic administration of interleukin-2 protects mice from lethal challenge with gram-negative bacteria. Infect Immun (1987) 1.13
Interleukin 2-diphtheria toxin fusion protein can abolish cell-mediated immunity in vivo. Proc Natl Acad Sci U S A (1988) 1.10
On the role of sIL-2R measurements in rheumatoid arthritis and cancers. Mediators Inflamm (2005) 1.09
Normal and certain leukaemic B cells express IL-2 receptors without in vitro activation. Clin Exp Immunol (1986) 1.05
Implications for the role of cognate interactions in in vitro human B cell activation by Staphylococcus aureus Cowan I and pokeweed mitogen. J Clin Invest (1986) 1.03
Defective expression of T cell-associated glycoprotein in severe combined immunodeficiency. J Clin Invest (1986) 1.02
Administration of recombinant interleukin 2 in vivo induces a polyclonal IgM response. J Exp Med (1986) 1.00
Identification of interleukin-2 in human peripheral blood eosinophils. Immunology (1996) 0.99
IL-2 receptor expression in human lymphoid lesions. Immunohistochemical study of 166 cases. Am J Pathol (1987) 0.97
Regulation by recombinant interleukin-2 of protective immunity against recurrent herpes simplex virus type 2 genital infection in guinea pigs. J Virol (1987) 0.97
Terminal maturation of resting B cells by proliferation-independent B cells differentiation factors. J Exp Med (1986) 0.97
Soluble interleukin-2 receptor, interleukin-2 and interleukin-4 in sera and supernatants from patients with progressive systemic sclerosis. Clin Exp Immunol (1990) 0.97
The interleukins in acquired disease. Clin Exp Immunol (1988) 0.96
Phenotypic knockout of the high-affinity human interleukin 2 receptor by intracellular single-chain antibodies against the alpha subunit of the receptor. Proc Natl Acad Sci U S A (1995) 0.94
Differential mechanism for differentiation into immunoglobulin-secreting cells in human resting B lymphocyte subsets isolated on the basis of cell density. J Clin Invest (1988) 0.94
Serum interleukin-2-receptor in coeliac disease: response to treatment and gluten challenge. Clin Exp Immunol (1989) 0.94
Lung-protective effects of the metalloporphyrinic peroxynitrite decomposition catalyst WW-85 in interleukin-2 induced toxicity. Biochem Biophys Res Commun (2008) 0.93
IL-21 signalling via STAT3 primes human naive B cells to respond to IL-2 to enhance their differentiation into plasmablasts. Blood (2013) 0.93
Development of plasmacytoid cells with Russell bodies in autoimmune "viable motheaten" mice. Am J Pathol (1987) 0.93
Expression of Tac antigen in B cell lymphomas. Clin Exp Immunol (1986) 0.92
Distribution of lymphocytes with interleukin-2 receptors (TAC antigens) in reactive lymphoproliferative processes, Hodgkin's disease, and non-Hodgkin's lymphomas. An immunohistologic study of 300 cases. Am J Pathol (1987) 0.91
A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part II: Immunological aspects. Br J Cancer (1993) 0.90
Case of autoimmune hepatitis with markedly enlarged hepatoduodenal ligament lymph nodes. World J Gastroenterol (2013) 0.90
Influence of IL-2 and IL-4 on the IgE synthesis and the IgE-binding factor (sCD23) production by human lymphocytes in vitro. Immunology (1989) 0.87
Identification of a cDNA for a human high-molecular-weight B-cell growth factor. Proc Natl Acad Sci U S A (1993) 0.86
Direct induction of human B-cell differentiation by recombinant interleukin-2. Immunology (1986) 0.86
B lymphocyte reconstitution after human bone marrow transplantation. Leu-1 antigen defines a distinct population of B lymphocytes. J Clin Invest (1987) 0.84
A promoter element that exerts positive and negative control of the interleukin 2-responsive J-chain gene. Proc Natl Acad Sci U S A (1992) 0.83
Immunoglobulin production of human lymphocytes stimulated by Staphylococcus aureus Cowan I and pokeweed mitogen: differential effects of recombinant interleukin-2. Immunology (1986) 0.83
Phase I study of intra-arterial interleukin-2 in squamous cell carcinoma of the head and neck. Br J Cancer (1992) 0.83
Production of interleukin 2 in multiple myeloma. Clin Exp Immunol (1986) 0.82
Direct effect of interleukin 2 on chronic lymphocytic leukaemia B cell functions and morphology. Clin Exp Immunol (1987) 0.81
Expression of IL-2 receptor p55 and p75 chains by human B lymphocytes: effects of activation and differentiation. Immunology (1991) 0.79
IL-2 infusion abrogates humoral immune responses in humans. Clin Exp Immunol (1992) 0.79
Expression of human CD antigens, including CD1 and CD25, by human x mouse interlineage leukaemia hybrids. Immunology (1987) 0.79
Serum soluble interleukin-2 receptor level as a prognostic indicator in gastric cancer. Br J Cancer (1998) 0.79
Characterisation and expression analysis of interleukin 2 (IL-2) and IL-21 homologues in the Japanese pufferfish, Fugu rubripes, following their discovery by synteny. Immunogenetics (2004) 0.78
Pro-Inflammatory Cytokines Predict Relapse-Free Survival after One Month of Interferon-α but Not Observation in Intermediate Risk Melanoma Patients. PLoS One (2015) 0.78
Expression of novel interleukin 2 binding molecules and their functional roles in human B cell differentiation. J Clin Invest (1988) 0.78
Methotrexate and a spleen tyrosine kinase inhibitor cooperate to inhibit responses to peripheral blood B cells in rheumatoid arthritis. Pharmacol Res Perspect (2013) 0.78
Blockade of the interleukin-2 receptor by anti-Tac antibody inhibits the generation of antigen-nonspecific suppressor T cells in vitro. Proc Natl Acad Sci U S A (1988) 0.77
cDNA cloning of ovine interleukin 2 by PCR. Nucleic Acids Res (1990) 0.77
CpG methylation changes within the IL2RA promoter in type 1 diabetes of childhood onset. PLoS One (2013) 0.76
Immunophenotyping of non-Hodgkin's lymphoma. Correlation with relapse-free survival. Am J Pathol (1988) 0.76
Studies using the anti-idiotypic monoclonal antibody 105AD7 in patients with primary and advanced colorectal cancer. Ann R Coll Surg Engl (2002) 0.76
The role of the multichain IL-2 receptor complex in the control of normal and malignant T-cell proliferation. Environ Health Perspect (1987) 0.76
Synovial fluid mononuclear cells exhibit a spontaneous HLA-DR driven proliferative response. Clin Exp Immunol (1987) 0.76
Guidelines for information about therapy experiments: a proposal on best practice for recording experimental data on cancer therapy. BMC Res Notes (2012) 0.75
IL-2 enhances polyclonal IgM but not IgM-rheumatoid factor synthesis by activated human peripheral blood B cells. Clin Exp Immunol (1993) 0.75
Interleukin-2 receptors on rat eosinophils in adjuvant arthritis. Immunology (1991) 0.75
Activation of lymphocytes after platelet allotransfusion possessing only class I MHC product. Clin Exp Immunol (1990) 0.75
Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose. Immunochemistry (1978) 22.56
A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. J Immunol (1981) 10.92
T cell growth factor receptors. Quantitation, specificity, and biological relevance. J Exp Med (1981) 10.66
A monoclonal antibody that appears to recognize the receptor for human T-cell growth factor; partial characterization of the receptor. Nature (1982) 9.42
Role of suppressor T cells in pathogenesis of common variable hypogammaglobulinaemia. Lancet (1974) 8.13
Regulation of B-cell growth and differentiation by soluble factors. Annu Rev Immunol (1983) 5.09
T cell-derived B cell differentiation factor(s). Effect on the isotype switch of murine B cells. J Exp Med (1982) 4.51
Ultra-rapid fluorescent labelling of proteins. Nature (1962) 3.77
B cell helper factors. I. Requirement for both interleukin 2 and another 40,000 mol wt factor. J Exp Med (1981) 3.40
Site-specific mutagenesis of the human interleukin-2 gene: structure-function analysis of the cysteine residues. Science (1984) 3.29
Tritium labeling of proteins to high specific radioactivity by reduction methylation. J Biol Chem (1980) 3.04
Antigen-induced T cell-replacing factor (TRF). III. Establishment of T cell hybrid clone continuously producing TRF and functional analysis of released TRF. J Immunol (1980) 2.95
Direct demonstration of the identity of T cell growth factor binding protein and the Tac antigen. J Exp Med (1983) 2.82
Characterization of the human receptor for T-cell growth factor. Proc Natl Acad Sci U S A (1983) 2.76
T cell-dependent activation of resting B cells: requirement for both nonspecific unrestricted and antigen-specific Ia-restricted soluble factors. Proc Natl Acad Sci U S A (1981) 2.74
Rearrangement and expression of immunoglobulin genes and expression of Tac antigen in hairy cell leukemia. Proc Natl Acad Sci U S A (1983) 2.73
Blockade of the interleukin-2 receptor by anti-Tac antibody: inhibition of human lymphocyte activation. J Immunol (1983) 2.65
The Sézary syndrome: a malignant proliferation of helper T cells. J Clin Invest (1976) 2.32
Production of a B cell growth-promoting activity, (DL)BCGF, from a cloned T cell line and its assay on the BCL1 B cell tumor. J Exp Med (1982) 2.22
Separable helper factors support B cell proliferation and maturation to Ig secretion. J Immunol (1982) 2.16
Purification and partial sequence analysis of human T-cell growth factor. Proc Natl Acad Sci U S A (1983) 2.09
Proliferative responses of normal human B lymphocytes. Development of an assay system for human B cell growth factor (BCGF). J Immunol (1982) 2.02
Polyclonal B-cell activators in the study of the regulation of immunoglobulin synthesis in the human system. Adv Immunol (1982) 1.85
Texas Red, a hydrophilic, red-emitting fluorophore for use with fluorescein in dual parameter flow microfluorometric and fluorescence microscopic studies. J Immunol Methods (1982) 1.80
Antibodies in human sera reactive against an internal structural protein of human T-cell lymphoma virus. Nature (1981) 1.79
Interleukin 2 induces antigen-reactive T cell lines to secrete BCGF-I. J Exp Med (1983) 1.71
B cell growth and differentiation factors and mechanism of B cell activation. Immunol Rev (1984) 1.57
Proliferation and differentiation of single hapten-specific B lymphocytes is promoted by T-cell factor(s) distinct from T-cell growth factor. Proc Natl Acad Sci U S A (1982) 1.53
T cell replacing factors in the B cell response to antigen. Immunol Rev (1982) 1.44
Induction of Fc epsilon-receptor bearing cells in vitro in human peripheral lymphocytes. J Immunol (1980) 1.39
T cells with Fc receptors for IgA: induction of T alpha cells in vivo and in vitro by purified IgA. J Immunol (1981) 1.27
Serologic cross-reactivity between Class I MHC molecules and an H-2-linked differentiation antigen as detected by monoclonal antibodies. J Exp Med (1984) 1.25
Insulin-induced increase in insulin binding to cultured chondrosarcoma chondrocytes. J Biol Chem (1983) 1.02
Interactions between the receptors for insulin and the insulin-like growth factors on adipocytes. J Biol Chem (1982) 1.00
Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science (2001) 23.42
Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell (1993) 20.72
Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature (1990) 14.46
BCL-2 family members and the mitochondria in apoptosis. Genes Dev (1999) 13.52
A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. J Immunol (1981) 10.92
Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell (1993) 10.83
Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L) Cell (1996) 10.83
T cell growth factor receptors. Quantitation, specificity, and biological relevance. J Exp Med (1981) 10.66
A monoclonal antibody that appears to recognize the receptor for human T-cell growth factor; partial characterization of the receptor. Nature (1982) 9.42
BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol Cell (2001) 9.33
NF-kappa B controls expression of inhibitor I kappa B alpha: evidence for an inducible autoregulatory pathway. Science (1993) 9.03
The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. Mol Cell (2000) 8.95
Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell (1995) 8.75
tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c. Genes Dev (2000) 8.35
bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell (1991) 8.13
Role of suppressor T cells in pathogenesis of common variable hypogammaglobulinaemia. Lancet (1974) 8.13
Molecular cloning and expression of cDNAs for the human interleukin-2 receptor. Nature (1984) 7.37
Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell (1985) 7.29
Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell (1993) 7.25
Bax-deficient mice with lymphoid hyperplasia and male germ cell death. Science (1995) 6.84
Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell (1993) 6.83
Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science (2001) 6.79
BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature (1994) 6.69
bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell (1989) 6.66
Altered Hox expression and segmental identity in Mll-mutant mice. Nature (1995) 6.60
Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective defect in soluble antigen recognition. N Engl J Med (1985) 6.46
Low and high affinity cellular receptors for interleukin 2. Implications for the level of Tac antigen. J Exp Med (1984) 6.45
BCL-2 family: regulators of cell death. Annu Rev Immunol (1998) 6.41
Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. Nature (1999) 6.37
Cell death in development. Cell (1999) 6.01
BID: a novel BH3 domain-only death agonist. Genes Dev (1996) 5.90
Enforced dimerization of BAX results in its translocation, mitochondrial dysfunction and apoptosis. EMBO J (1998) 5.78
Metabolism of immunoglobulins. Prog Allergy (1969) 5.74
BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci U S A (1991) 5.50
Co-adjuvant effects of retinoic acid and IL-15 induce inflammatory immunity to dietary antigens. Nature (2011) 5.41
The same inducible nuclear proteins regulates mitogen activation of both the interleukin-2 receptor-alpha gene and type 1 HIV. Cell (1988) 5.33
Isolation of single-copy human genes from a library of yeast artificial chromosome clones. Science (1989) 5.29
Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J Immunol (1990) 5.26
Interleukin-2 receptor gamma chain: a functional component of the interleukin-7 receptor. Science (1993) 5.22
Activation of the HIV-1 LTR by T cell mitogens and the trans-activator protein of HTLV-I. Science (1987) 5.22
The human immunodeficiency virus-1 nef gene product: a positive factor for viral infection and replication in primary lymphocytes and macrophages. J Exp Med (1994) 5.22
Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood (1996) 5.13
Regulatory pathways governing HIV-1 replication. Cell (1989) 4.97
Cyclosporin A inhibits T-cell growth factor gene expression at the level of mRNA transcription. Proc Natl Acad Sci U S A (1984) 4.90
The v-rel oncogene encodes a kappa B enhancer binding protein that inhibits NF-kappa B function. Cell (1990) 4.87
Clustered arrangement of immunoglobulin lambda constant region genes in man. Nature (1981) 4.87
Identification and initial characterization of a rat monoclonal antibody reactive with the murine interleukin 2 receptor-ligand complex. Proc Natl Acad Sci U S A (1983) 4.83
HTLV-I tax induces cellular proteins that activate the kappa B element in the IL-2 receptor alpha gene. Science (1988) 4.77
Regulation of the human interleukin-2 receptor alpha chain promoter: activation of a nonfunctional promoter by the transactivator gene of HTLV-I. Cell (1987) 4.76
Demonstration of a non-Tac peptide that binds interleukin 2: a potential participant in a multichain interleukin 2 receptor complex. Proc Natl Acad Sci U S A (1986) 4.61
Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death. J Biol Chem (1999) 4.56
Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency. Nat Genet (1998) 4.32
Novel interleukin-2 receptor subunit detected by cross-linking under high-affinity conditions. Science (1986) 4.30
The gene SCL is expressed during early hematopoiesis and encodes a differentiation-related DNA-binding motif. Proc Natl Acad Sci U S A (1989) 4.22
Multiple Bcl-2 family members demonstrate selective dimerizations with Bax. Proc Natl Acad Sci U S A (1995) 4.22
BAX-induced cell death may not require interleukin 1 beta-converting enzyme-like proteases. Proc Natl Acad Sci U S A (1996) 4.20
Regulated targeting of BAX to mitochondria. J Cell Biol (1998) 4.17
Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14; 18). Nature (1991) 4.06
BAX is required for neuronal death after trophic factor deprivation and during development. Neuron (1996) 4.02
BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Mol Cell Biol (1999) 4.00
Alternative promoters and exons, somatic mutation and deregulation of the Bcl-2-Ig fusion gene in lymphoma. EMBO J (1988) 3.77
Interleukin 2 (IL-2) augments transcription of the IL-2 receptor gene. Proc Natl Acad Sci U S A (1985) 3.74
Developmental hierarchy of immunoglobulin gene rearrangements in human leukemic pre-B-cells. Proc Natl Acad Sci U S A (1981) 3.73
Identification of HTLV-I tax trans-activator mutants exhibiting novel transcriptional phenotypes. Genes Dev (1990) 3.67
Comparison of the ion channel characteristics of proapoptotic BAX and antiapoptotic BCL-2. Proc Natl Acad Sci U S A (1997) 3.66
Human immunoglobulin kappa light-chain genes are deleted or rearranged in lambda-producing B cells. Nature (1981) 3.64
BAX-dependent transport of cytochrome c reconstituted in pure liposomes. Nat Cell Biol (2000) 3.53
Metabolic properties of IgG subclasses in man. J Clin Invest (1970) 3.48
Kappa B-specific DNA binding proteins: role in the regulation of human interleukin-2 gene expression. Science (1989) 3.48
Phosphorylation and inactivation of BAD by mitochondria-anchored protein kinase A. Mol Cell (1999) 3.46
Checkpoints of dueling dimers foil death wishes. Cell (1994) 3.45
Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I. Science (1995) 3.43
Nef protein of human immunodeficiency virus type 1: evidence against its role as a transcriptional inhibitor. Proc Natl Acad Sci U S A (1989) 3.43
Activation of interleukin 2 and interleukin 2 receptor (Tac) promoter expression by the trans-activator (tat) gene product of human T-cell leukemia virus, type I. Proc Natl Acad Sci U S A (1987) 3.43
Cloning of a receptor subunit required for signaling by thymic stromal lymphopoietin. Nat Immunol (2000) 3.42
Dynamic disruptions in nuclear envelope architecture and integrity induced by HIV-1 Vpr. Science (2001) 3.37
Prevention of lymphocyte cell death in sepsis improves survival in mice. Proc Natl Acad Sci U S A (1999) 3.35
The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes. Science (1986) 3.32
Functional replacement of the HIV-1 rev protein by the HTLV-1 rex protein. Nature (1988) 3.31
Expression of the Bcl-2 protein in murine and human thymocytes and in peripheral T lymphocytes. J Immunol (1993) 3.28